Top Markets
#1 MowCat MowCat +48.89%
#2 Bermuda Shorts Bermuda Shorts +30.33%
#3 Velvet Velvet +26.11%
#4 Biconomy Biconomy +24.38%
#5 aPriori aPriori +22.89%
#6 Derive Derive +19.95%
#7 Audiera Audiera +18.63%
#8 Quack AI Quack AI +16.83%
#9 Perle Perle +13.71%
#10 Block Street Block Street +10.44%
Coin of the day
MowCat MowCat
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Mustang Bio, Inc. Mustang Bio, Inc.

Mustang Bio, Inc.

MBIO
Clasificación en acciones #35075
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on... Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Precio por acción
$0.594
Última sincronización: 2026-08-14
Capitalización bursátil
$4.50M
Cambio (1 día)
0.00%
Cambio (1 año)
-66.44%
País
US
Comercio Mustang Bio, Inc. (MBIO)

Categoría

Healthcare
Ganancias de Mustang Bio, Inc. (MBIO)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Mustang Bio, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Mustang Bio, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE